SCHEMBL6568018

SCHEMBL6568018

COC(=O)c1ccc(OC(C)C)c(OC)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.66
ALDH1A1 P00352 3/20 0.60
MAPK1 P28482 1/20 0.60
KMT2A Q03164 6/20 0.59
SMN1; SMN2 Q16637 3/20 0.54
NPC1 O15118 2/20 0.54
RAB9A P51151 2/20 0.54
TP53 P04637 1/20 0.54
TSHR P16473 2/20 0.53
CYP1A2 P05177 2/20 0.53
CYP3A4 P08684 2/20 0.53
CYP2C9 P11712 2/20 0.53
CYP2C19 P33261 2/20 0.53
PKM P14618 1/20 0.52
CA12 O43570 1/20 0.51
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
CA4 P22748 1/20 0.51
CA6 P23280 1/20 0.51
CA7 P43166 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28663604 0.93 MAPT (0.66) MAPTALDH1A1MAPK1KMT2ASMN1; SMN2
SCHEMBL8886754 0.89 ALDH1A1 (0.55) MAPTALDH1A1MAPK1KMT2ASMN1; SMN2
SCHEMBL3470599 0.89 MAPT (0.64) MAPTALDH1A1MAPK1KMT2ASMN1; SMN2
SCHEMBL3132688 0.87 MAPT (0.62) MAPTALDH1A1MAPK1KMT2ASMN1; SMN2
SCHEMBL6276416 0.87 MAPT (0.62) MAPTALDH1A1MAPK1KMT2ASMN1; SMN2
SCHEMBL5755306 0.86 MAPT (0.60) MAPTALDH1A1MAPK1KMT2ASMN1; SMN2
SCHEMBL24079281 0.86 MAPT (0.49) MAPTALDH1A1MAPK1KMT2ASMN1; SMN2
Veratric Acid Methyl Ester SCHEMBL2050732 0.86 MAPT (0.86) MAPTALDH1A1KMT2ASMN1; SMN2NPC1
Veratric Acid Methyl Ester SCHEMBL29573244 0.86 MAPT (0.86) MAPTALDH1A1KMT2ASMN1; SMN2NPC1
SCHEMBL3738587 0.85 MAPT (0.64) MAPTMAPK1KMT2ASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11021444-B2 Antiviral compounds Janssen Biopharma, Inc. (US) 2021-06-01 US disclosed
US-20190263754-A1 ANTIVIRAL COMPOUNDS ALIOS BIOPHARMA, INC. (US) 2019-08-29 US disclosed
US-20180065932-A1 ANTIVIRAL COMPOUNDS ALIOS BIOPHARMA, INC. 2018-03-08 US disclosed
US-20180065932-A1 ANTIVIRAL COMPOUNDS ALIOS BIOPHARMA, INC. 2018-03-08 US disclosed
US-20150065504-A1 ANTIVIRAL COMPOUNDS ALIOS BIOPHARMA, INC. 2015-03-05 US disclosed
US-20150065504-A1 ANTIVIRAL COMPOUNDS ALIOS BIOPHARMA, INC. 2015-03-05 US disclosed
US-20040259912-A1 Benzine derivatives, process for preparing the same and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-12-23 US disclosed
EP-1437344-A1 BENZENE DERIVATIVES,PROCESS FOR PREPARING THE SAME AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2004-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190263754-A1 ANTIVIRAL COMPOUNDS MAVS, SARS1, ZC3HAV1 MAPT 4665/4885ALDH1A1 4011/4885MAPK1 4304/4885
US-11021444-B2 Antiviral compounds MAVS, SARS1, ZC3HAV1 MAPT 4665/4885ALDH1A1 4011/4885MAPK1 4304/4885
US-20180065932-A1 ANTIVIRAL COMPOUNDS MAVS, SARS1, ZC3HAV1 MAPT 4665/4885ALDH1A1 4011/4885MAPK1 4304/4885
US-20150065504-A1 ANTIVIRAL COMPOUNDS MAVS, SARS1, ZC3HAV1 MAPT 4665/4885ALDH1A1 4011/4885MAPK1 4304/4885
US-20040259912-A1 Benzine derivatives, process for preparing the same and use thereof HRH4, HRH2, HRH1 MAPT 4743/4885ALDH1A1 907/4885MAPK1 1934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.